Moreover, the 36-month beta value for XRTX is 0.49. Analysts have varying opinions on the stock, with 1 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for XRTX is 3.36M and currently, short sellers hold a 0.73% of that float. On February 24, 2025, XRTX’s average trading volume was 112.95K shares.
XRTX) stock’s latest price update
The stock price of XORTX Therapeutics Inc (NASDAQ: XRTX) has dropped by -13.23 compared to previous close of 0.94. Despite this, the company has seen a fall of -14.58% in its stock price over the last five trading days. globenewswire.com reported 2025-01-17 that CALGARY, Alberta, Jan. 17, 2025 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“XORTX” or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease and gout, announces the Company has changed its auditor from Smythe LLP, Chartered Professional Accountants (“Former Auditor”) to Davidson & Company LLP, Chartered Professional Accountants, (“Successor Auditor”) effective January 16, 2025.
XRTX’s Market Performance
XORTX Therapeutics Inc (XRTX) has experienced a -14.58% fall in stock performance for the past week, with a -15.60% drop in the past month, and a -33.56% drop in the past quarter. The volatility ratio for the week is 9.28%, and the volatility levels for the past 30 days are at 7.61% for XRTX. The simple moving average for the past 20 days is -10.60% for XRTX’s stock, with a -49.12% simple moving average for the past 200 days.
XRTX Trading at -22.34% from the 50-Day Moving Average
After a stumble in the market that brought XRTX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -88.29% of loss for the given period.
Volatility was left at 7.61%, however, over the last 30 days, the volatility rate increased by 9.28%, as shares sank -10.72% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -28.70% lower at present.
During the last 5 trading sessions, XRTX fell by -14.58%, which changed the moving average for the period of 200-days by -69.37% in comparison to the 20-day moving average, which settled at $0.9172. In addition, XORTX Therapeutics Inc saw -27.41% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for XRTX
The total capital return value is set at -3.22. Equity return is now at value -17.92, with -14.04 for asset returns.
Based on XORTX Therapeutics Inc (XRTX), the company’s capital structure generated 0.03 points at debt to capital in total, while cash flow to debt ratio is standing at -66.54.
Currently, EBITDA for the company is -4.87 million with net debt to EBITDA at 0.56. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.40.
Conclusion
To wrap up, the performance of XORTX Therapeutics Inc (XRTX) has been bad in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
